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Abstract
The interferon-induced dynamin-like MxA GTPase restricts the replication of influenza A viruses. We identified adaptive
mutations in the nucleoprotein (NP) of pandemic strains A/Brevig Mission/1/1918 (1918) and A/Hamburg/4/2009 (pH1N1)
that confer MxA resistance. These resistance-associated amino acids in NP differ between the two strains but form a similar
discrete surface-exposed cluster in the body domain of NP, indicating that MxA resistance evolved independently. The 1918
cluster was conserved in all descendent strains of seasonal influenza viruses. Introduction of this cluster into the NP of the
MxA-sensitive influenza virus A/Thailand/1(KAN-1)/04 (H5N1) resulted in a gain of MxA resistance coupled with a decrease in
viral replication fitness. Conversely, introduction of MxA-sensitive amino acids into pH1N1 NP enhanced viral growth in Mx-
negative cells. We conclude that human MxA represents a barrier against zoonotic introduction of avian influenza viruses
and that adaptive mutations in the viral NP should be carefully monitored.
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Introduction
Avian influenza A viruses sporadically transmit from waterfowl,
their natural reservoir, into the human population [1–5]. These
zoonotic viruses usually cannot propagate in the new human host,
nor do they readily transmit between humans [6–8]. In rare cases,
however, influenza A viruses of avian origin break the species
barrier and establish new virus lineages in humans. In the last 100
years, the introduction of an influenza A virus with a novel
nucleoprotein (NP) gene segment occurred only on two occasions,
both of which led to pandemics: in 1918 (‘‘Spanish’’ H1N1) an
avian virus and in 2009 (pH1N1) a reassortant virus (comprising
gene segments of two swine influenza viruses) established a stable
lineage in humans [9,10]. In contrast, the 1957 (‘‘Asian’’ H2N2)
and the 1968 (‘‘Hong-Kong’’ H3N2) pandemics were caused by
genetic reassortment events, whereby the circulating human
strains acquired some gene segments from avian sources but kept,
among others, their 1918-derived NP [11].
To overcome the species barrier, multiple adaptations to the
new host are required [6]. Theoretically, two categories of
adaptive mechanisms can be envisaged. One comprises adapta-
tions to cellular factors which promote viral infection yet differ
between hosts. These include, for example, changes in the viral
hemagglutinin during the adaptation of avian influenza A viruses
to humans [12], or altered binding of viral proteins to different
cellular importins [11,13]. The second category comprises
adaptations to counteract cellular restriction factors that inhibit
virus replication. These factors are part of the intrinsic and innate
host defense mechanisms and may exert a strong selective pressure
against newly invading viruses. Surprisingly little is known about
adaptive mutations that overcome such host restriction factors and
facilitate trans-species transmission of influenza viruses.
The human interferon (IFN) system represents a major innate
defense against zoonotic viruses. Among the many antiviral factors
induced by IFNs, the MxA protein is one of the most potent
characterized to date [14]. It is a key effector molecule inhibiting
influenza A virus as well as several other human RNA viruses
[15,16]. MxA is a dynamin-like large GTPase which consists of an
N-terminal globular GTPase domain, a bundle signaling element,
and a C-terminal helical stalk. The recent atomic resolution of the
MxA structure revealed that it forms stable tetramers and
oligomers which assemble in a criss-cross manner via the stalk
[17,18]. A current model proposes that, upon viral infection, MxA
recognizes the incoming vRNPs and starts to self-assemble into
rings, resulting in a higher-order oligomeric complex that blocks
vRNP function [18,19].
In accordance with this model, recent findings suggest that NP
determines the relative sensitivity of influenza A viruses toward the
antiviral action of MxA. Avian influenza viruses were found to be
generally more sensitive to MxA than human strains [20], which
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was subsequently shown through reassortant viruses to be
dependent on the origin of NP [21]. These findings suggest that
human strains acquire adaptive mutations in NP to evade MxA
restriction.
Here, we identified the amino acids critical for MxA resistance
in the two NP proteins introduced into the human population in
1918 (by the ‘‘Spanish’’ H1N1 influenza A virus) and in 2009 (by
the pH1N1 strain). These residues clustered into two distinct but
overlapping ‘‘patches’’ in the body domain of the protein.
Introduction of these amino acids into an MxA-sensitive H5N1
NP was sufficient to render the avian polymerase resistant to MxA.
Surprisingly, the resistance-associated substitutions resulted in
impaired viral growth in both mammalian and avian cells when
introduced into recombinant H5N1 virus A/Thailand/1(KAN-1)/
04. The amino acid clusters identified here are highly conserved in
circulating human isolates and virtually absent in NPs of avian
influenza A viruses. Several of the amino acids that confer
increased resistance to human MxA are also conserved in
influenza A viruses of the classical swine lineage, correlating with
resistance of these viruses to swine Mx1. These findings suggest
that multiple adaptive amino acid changes would be required for
H5N1 viruses to both escape from MxA restriction and maintain
viral fitness. Partial adaptation in an intermediate host, such as the
pig, might facilitate this demanding process.
Results
Identification of residues in NP of the pandemic 1918
influenza A virus responsible for resistance to murine
Mx1
We have previously shown that the polymerase activity of A/
Thailand/1(KAN-1)/04 (H5N1) is highly sensitive to inhibition by
murine Mx1, a close homolog of human MxA, in a polymerase
reconstitution assay, and that this sensitivity is determined by the
NP gene [21]. The H5N1 NP is of typical avian origin and
resembles the avian H5N1 amino acid consensus sequence [21].
We therefore used this assay to identify the amino acids in NP of
either the 1918 (A/Brevig Mission/1/1918) or the 2009 (A/
Hamburg/4/2009) pandemic H1N1 strain (Figure 1A) critical for
Mx1 resistance. In this assay, the polymerase activity was
measured in the presence of overexpressed Mx1. In addition, we
determined the polymerase activity in the presence of the inactive
mutant Mx1-K49A [22]. Mx1 resistance was defined as the
relative activity of the viral polymerase in the presence of Mx1
divided by the activity obtained with Mx1-K49A. Substitution of
the H5N1 NP with the NP of the pandemic 1918 strain [23]
rendered the H5N1 polymerase largely Mx1-resistant (Figure 1B).
An alignment of the amino acid sequences of the 1918 NP with the
NP of the Mx1-sensitive H5N1 strain revealed differences at 14
positions, including 4 positions in the C-terminal domain, namely
amino acids 373, 377, 473 and 482 (Figure 1A). An artificial
chimera (1918*-NP), consisting of the N-terminal 365 amino acids
of the 1918 NP and the C-terminal domain (amino acids 366 to
498) of the H5N1 NP, behaved like the full-length 1918 NP,
indicating that the 4 C-terminal differences in the 1918 protein do
not contribute to the Mx1 resistance phenotype (Figure 1B). To
investigate which of the 10 remaining 1918-specific amino acids in
the chimeric protein contributed to Mx1 resistance, 1918*-NP
mutants harboring single H5N1-derived substitutions were tested.
A major decrease in Mx1 resistance was observed for the
mutations P283L and Y313F, while a less pronounced phenotype
was observed for I100R and several other mutants (Figure 1C).
Various combinations of these putative adaptive mutations
revealed that the triple mutant I100R, P283L, and Y313F led to
a similar degree of Mx1 sensitivity as observed using the H5N1 NP
(Figure 1D), whereas combinations of the remaining seven
mutations failed to reduce Mx1 resistance (Figure 1D). Consis-
tently, the 1918*-NP, carrying the mutations I100R, P283L and
Y313F reduced Mx1 resistance by 50% (as compared to 1918*-
NP) also in the context of the 1918 polymerase (Figure S1A–B).
To test whether the amino acids apparently responsible for Mx1
resistance of 1918 NP could also confer Mx1 resistance to an Mx1-
sensitive NP, we introduced the mutations R100I, L283P, and
F313Y into H5N1 NP. We also tested the exchange R100V in NP,
since screening of the NCBI influenza database revealed that
valine rather than isoleucine is commonly found at this position in
seasonal strains [24]. Single amino acid exchanges slightly
increased Mx1 resistance, while the combination of all three
substitutions resulted in resistance comparable to the 1918 NP,
irrespective of I or V at position 100 (Figure 1E). Importantly, this
enhanced Mx1 resistance was not simply achieved by a higher
polymerase activity, as it did not strictly correlate with increased
activity in the presence of the antivirally inactive mutant Mx1-
K49A. Nevertheless, some Mx1 resistance-enhancing amino acids
appeared to improve the polymerase activity for unknown reasons
in the absence of Mx1 or presence of Mx1-K49A protein (Figure
S1C).
The cluster of adaptive mutations conferring Mx1
resistance differs between pH1N1 and 1918 NP
Next, we evaluated the capacity of NP from the 2009 pandemic
H1N1 influenza A virus (pH1N1) to confer Mx1 resistance in the
context of the H5N1 polymerase. Figure 2A shows that pH1N1
NP rendered the H5N1 polymerase activity relatively resistant to
Mx1 inhibition, as previously reported [21]. Sequence compari-
sons between the NP of pH1N1 and H5N1 origin revealed that
pH1N1 NP carried only one (V100) out of the three Mx1
resistance determinants identified in 1918 NP (Figure 1A). We
therefore assumed that different amino acids contribute to Mx1
resistance in pH1N1 NP than in 1918 NP. Since the pH1N1 NP
Author Summary
Influenza A viruses of avian or swine origin sporadically
enter into the human population but do not transmit
between individuals. In rare cases, however, they establish
a new virus lineage in humans. The mechanisms by which
invading viruses overcome the species barrier are not well
understood, but multiple adaptations to the new host are
required. Surprisingly little is known about adaptive
mutations that overcome restriction factors of the intrinsic
and innate host defense system. In this study, we have
identified adaptive mutations in pandemic strains A/Brevig
Mission/1/1918 and A/Hamburg/4/2009 that confer resis-
tance to the interferon-induced antiviral factor MxA which
is a dynamin-like large GTPase that recognizes the
incoming viral nucleocapsids and blocks their function.
The resistance-enhancing mutations changed several
amino acids in the viral nucleoprotein which is the main
nucleocapsid component. These mutations were sufficient
to increase the pathogenicity of an avian influenza virus
strain in a Mx-positive mouse model. Interestingly, the
resistance-associated amino acids are counter-selected in
circulating avian influenza strains, because they compro-
mise general viral replication fitness. The present data
indicate that the innate immunity factor MxA provides a
barrier against zoonotic introduction of influenza A viruses
and that adaptive mutations in the nucleoprotein must be
carefully monitored.
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Figure 1. Identification of residues in the NP of the pandemic 1918 influenza A virus responsible for resistance to murine Mx1. (A)
Amino acid differences between NP of H5N1, 1918 and pH1N1. Deviant amino acids of pH1N1 or 1918 NP are highlighted in red and blue,
respectively. The 1918/H5N1 chimera (1918*-NP) comprises the N-terminal 365 amino acids of 1918 NP and the C-terminal 133 amino acids of the
H5N1 NP and thus lacks 4 1918 NP-specific amino acids. (B) Viral polymerase activity in the presence of increasing concentrations of Mx1. HEK293T
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differs by 32 amino acids from the H5N1 sequence (Figure 1A), we
did not assay all individual amino acid positions, but rather
focused on discordant and surface exposed amino acids in close
proximity (27 A˚) to the resistance cluster identified in the 1918 NP,
utilizing the published NP crystal structures [25,26]. Five of the
resulting 10 pH1N1-specific amino acids, which were closest to the
1918 resistance cluster, were analyzed in the H5N1 polymerase
reconstitution assay using pH1N1 NP mutants harboring single
H5N1-derived substitutions (Figure 2B). A significant decrease in
Mx1 resistance was observed for the mutations D53E, H289Y and
V313F, while a less pronounced phenotype was observed for
V100R and K305R (Figure 2B). Next, pH1N1-specific amino
acids were introduced into H5N1 NP and tested for their
contributions to Mx1 resistance in the H5N1 polymerase
reconstitution assay (Figure 2C). While no individual amino acid
substitution had a major effect, the combination of mutations at 4
positions (E53D, R100V, Y289H, and F313V) enhanced Mx1
resistance to a similar extent as 1918 NP. The additional
mutations R305K, I316M, T350K, R351K, V353I, and Q357K
together further increased Mx1 resistance to the degree of pH1N1
NP (Figure 2C). Although we observed variations in NP expression
levels (Figure 2C), these differences did not correlate with Mx
sensitivity. Together, these results demonstrate that the cluster of
amino acids conferring Mx1 resistance differs between the NP of
the 2009 and 1918 pandemic strains, although the crucial residues
in both cases are located in the surface-exposed body domain.
Adaptive mutations in NP confer resistance to both
murine Mx1 and human MxA
Next, we investigated whether the identified amino acid clusters
in NP of the 1918 and the pH1N1 strains also confer resistance to
human MxA. Consistent with the findings observed with Mx1,
both 1918 and pH1N1 NP increased resistance in the H5N1
polymerase reconstitution assay (Figure 3A), however, the 1918
NP confers greater resistance to human MxA than to murine Mx1,
whereas the opposite is true for the pH1N1 NP (Figure 2C and
3A). Importantly, the mutant H5N1 NP containing the 1918-
derived Mx1 resistance determinants R100V, L283P, and F313Y
exhibited an MxA resistance approximately 85% of that by 1918
NP itself (Figure 3A). To identify additional amino acid residues
that contribute to the increased MxA resistance of the 1918 NP,
we changed single amino acid positions in the 1918*-NP to avian
residues. This revealed that D16, in addition to V100, P283, and
Y313, contributed to MxA resistance (Figure S2). To confirm the
relevance of this finding, we tested H5N1 NP harboring all four
mutations (G16D, R100V, L283P and F313Y). This mutant NP
displayed an MxA resistance comparable to 1918 NP (Figure 3A).
Next, the pH1N1-specific adaptive mutations were tested in the
context of H5N1 NP. In particular E53D, R100V and F313V
increased resistance to MxA, while introduction of the additional
mutations Y289H, R305K, I316M, T350K, R351K V353I and
Q357K was required to achieve a resistance comparable to
pH1N1-NP (Figure 3A). These results indicate that the adaptive
mutations in 1918 or pH1N1 NP lead to increased resistance for
both murine Mx1 and human MxA. Again, the observed
resistance towards MxA did not strictly correlate with polymerase
activity (Figure S3).
The atomic crystal structure of the H5N1 NP [26] revealed that
the 1918-specific amino acids 100, 283 and 313 form a surface
exposed cluster in the body domain of the viral NP (Figure 3B).
Amino acid 16 is located in the N-terminal region of NP that is
predicted to form a flexible loop adjacent to the 1918 cluster
(Figure S4). The amino acids forming the pH1N1 cluster are
located in the same area of the NP body domain as the 1918
cluster (Figure 3C).
Positive selection of MxA resistance-enhancing NP
mutations in the human host
To estimate the evolutionary conservation of the amino acids
D16, D53, I/V100, P283, and V/Y313 mainly responsible for
Mx1 or MxA resistance (Figure 3B and C), we analyzed the NP
sequences of various isolates deposited in the NCBI Influenza
Virus Sequence Database [24]. In avian isolates, each resistance-
conferring amino acid could be identified in only #1% of the
sequences (n = 5350) investigated (Table 1). In contrast, in
classical seasonal human isolates representing H1N1, H1N2,
H2N2, and H3N2 subtypes (n = 4969), the resistance-associated
amino acids D16, I/V100, P283, and Y313 were each found at
very high frequencies (.98%). Similarly, analyses of the human-
derived pH1N1 NP sequences (n = 4104) revealed a high
conservation of amino acids D53, I/V100 and V313 (.99%).
Intriguingly, a chronological sequence comparison revealed that
additional Mx resistance-enhancing mutations occurred in the
NP of strains which are classified as descendents of the 1918
virus, namely R305K and R351K (Figure 4, Figure S5). These
mutations emerged in early seasonal H1N1 viruses and were
maintained in subsequent H2N2 and H3N2 strains (Figure 4).
Taken together, these findings suggest a continuous selection
pressure for increased Mx resistance in seasonal influenza
viruses.
NPs of the classical swine lineage confer partial resistance
to MxA
Since pH1N1 NP is derived from an influenza A virus of the
classical swine lineage [10,27], we analyzed the NP sequences of a
number (n = 393) of corresponding swine isolates obtained
between 1930 and 2012. Amino acids I/V100 were highly
conserved (.99%), but D53 and V313 were not present in any of
the NP sequences, which instead harbored the avian consensus
amino acids at these positions (Table 1). We therefore anticipated
that NPs of the classical swine influenza strains would confer less
MxA resistance than pH1N1 NP. Indeed, NP of one of the first
swine isolates such as A/swine/Iowa/1976/1931 displayed
comparatively poor MxA resistance in the H5N1 polymerase
reconstitution assay (Figure 5A). Importantly, NP of the classical
swine influenza A virus lineage acquired the additional mutations
305K, 351K, 353I and 357K over time (Figure 4), resulting in a
cells were transfected with expression plasmids coding for the PB2, PB1 and PA of H5N1, the indicated NP proteins, the firefly luciferase encoding
minigenome, increasing amounts of Mx1-coding plasmid and a Renilla-expressing plasmid to normalize variation in transfection efficiency.
Polymerase activity (relative activity) in the presence of antivirally inactive Mx1-K49A was used to normalize the data obtained with Mx1. Error bars
indicate the standard error of the mean of three independent experiments. Western blot analysis was performed to determine the expression levels
of Mx1 and H5N1 NP. (C–E) H5N1 polymerase activity was determined as in (B) after co-transfection of the expression plasmids coding for Mx1
(200 ng) and the indicated NP mutants (100 ng). The polymerase activity (relative activity) observed in the presence of Mx1 was normalized to Mx1-
K49A. The resulting relative activity in the presence of either 1918*NP (C–D) or 1918 NP (E) was set to 100%. Western blot analysis shown in panel (E)
was performed to determine the expression levels of NP. Error bars indicate the standard error of the mean of three independent experiments.
Student’s t-test was performed to determine the P value. *P,0.05, **P,0.01, ***P,0.001; NS, not significant.
doi:10.1371/journal.ppat.1003279.g001
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Figure 2. Identification of residues in the NP of the pandemic 2009 influenza A virus responsible for resistance to murine Mx1. (A)
Reporter activity of H5N1 polymerase in HEK293T cells after co-transfection of expression plasmids coding for the indicated NP proteins (100 ng) and
increasing amounts of Mx1. Polymerase activity in the presence of Mx1-K49A was used to normalize the data obtained with Mx1. Error bars indicate
the standard error of the mean of three independent experiments. (B) H5N1 polymerase activity (relative activity) was determined as in (A) after co-
transfection with expression plasmids coding for Mx1 (200 ng) and the indicated pH1N1 NP mutants (100 ng) harboring single H5N1-derived
substitutions. The activity in the presence of Mx1 was normalized to the activity observed with the inactive Mx1 mutant Mx1-K49A. The activity
observed in the presence of pH1N1 NP was set to 100%. Error bars indicate the standard error of the mean of three independent experiments.
Student’s t-test was performed to determine the P value. *P,0.05, **P,0.01, ***P,0.001; NS, not significant. (C) H5N1 polymerase activity was
determined as in (B) after co-transfection with expression plasmids coding for Mx1 (200 ng) and the indicated H5N1-NP mutant proteins (100 ng)
harboring single or multiple pH1N1-derived substitutions. The activity in the presence of Mx1 was normalized to the activity observed with the
inactive Mx1 mutant Mx1-K49A. The activity observed in the presence of 1918 NP was set to 100%. Western blot analysis shown in the lower panel
was performed to determine the expression levels of NP and Mx1. Error bars indicate the standard error of the mean of three independent
experiments. Student’s t-test was performed to determine the P value. *P,0.05, **P,0.01, ***P,0.001; NS, not significant.
doi:10.1371/journal.ppat.1003279.g002
Figure 3. Amino acid clusters in NP of both the 1918 and pH1N1 strainmediateMxA resistance. (A) H5N1 polymerase activity in HEK293T cells
after co-tranfection of the indicated expression plasmids coding for the NP mutants (100 ng) and MxA (200 ng). The activity in the presence of MxA was
normalized to the activity observedwith the inactivemutant MxA-T103A [66]. The activity observed in the presence of pH1N1 NPwas set to 100%. Error bars
indicate the standard error of the mean of three independent experiments. Student’s t-test was performed to determine the P value. *P,0.05, ***P,0.001,
NS, not significant. Western blot analysis was performed to determine the expression levels of MxA and the indicated NPs. (B–C) Amino acid positions of NP
mediating Mx resistance. The program PyMOL was used to assign the indicated positions based on the structural model of A/HK/483/97(H5N1) NP (PDB
code:2Q06). Positions of adaptive mutations required for Mx resistance of the 1918 NP are marked in blue (B). Amino acids of pH1N1 NP that exhibit only
minor contribution to Mx resistance are highlighted in light red, whereas amino acids that strongly increased Mx resistance are indicated in red (C).
doi:10.1371/journal.ppat.1003279.g003
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gradual increase in MxA resistance (Figure 5A, pH1N1-NP-D53E,
V313F, M316I, third column from the left and Figure S6A).
These changes, however, were not sufficient to confer MxA
resistance comparable to that of pH1N1 NP. Interestingly, NP of
the recent triple reassortant swine isolate A/swine/Ohio/02026/
2008 (H1N1) and a hypothetical NP precursor of pH1N1
(pH1N1-NP-D53E, V313F, M316I) share the adaptive mutations
100I/V, 289H, 305K, 350K, 351K, 353I and 357K. The
hypothetical NP precursor of pH1N1 was created by altering the
human pH1N1 specific positions D53, V313 and M316 to the
consensus found in classical swine H1N1 strains (D53E, V313F,
M316I). These mutations are found at the branching point of
classical swine influenza viruses and pH1N1 viruses (Figure 4).
The hypothetical NP precursor conferred only partial MxA
resistance in the H5N1 (Figure 5A and Figure S6A) as well as in
the pH1N1 background (Figure S6C). These findings suggested
that further adaptive mutations are needed which may affect
MxA recognition or otherwise improve NP functions such as
binding to viral (e.g PB2 [28] or cellular components (importins
[13], helicases [29,30]). Indeed, acquisition of E53D, F313V, and
I316M was required to gain the full resistance of pH1N1 NP
(Figure 5A and Figure S6C).
The antiviral potency of Mx proteins of pigs is still insufficiently
characterized [31–33]. In the present reconstitution assay using
HEK293T cells, porcine Mx1 (Sus scrofa domestica) decreased the
H5N1 polymerase activity to 50% (Figure 5B), whereas human
MxA reduced the activity to approximately 10% (Figure 5A),
despite similar expression levels of both Mx proteins (Figure 5C).
Likewise, the H5N1 polymerase activity in the presence of
different NPs from several distinct swine isolates was not
significantly affected by porcine Mx1 (Figure 5B, Figure S6B).
To further test the antiviral strength of porcine Mx, we used
porcine cells for the polymerase reconstitution assay. We found
essentially the same extent of inhibition by the porcine Mx1 as in
human 293T cells. As shown in Figure S7A, porcine Mx1 reduced
the H5N1 polymerase activity to ca. 50% in swine NPTr or NSK
cells [34]. In contrast, human MxA reduced the activity to 10% in
porcine cells (Figure S7A). We conclude that the antiviral effect of
porcine Mx1 is weak both in porcine and human cells. Together,
these data suggest that while there is a clear selection pressure for
swine influenza A viruses to acquire Mx resistance, the selection
pressure in the porcine host is comparatively weak. Clearly,
additional adaptive mutations are required to escape MxA
restriction in humans.
MxA resistance-enhancing mutations impair virus growth
Re-transmission of pH1N1 [35] from human to swine resulted
in 17% of the documented cases in a substitution of aspartic acid
at position 53 to the avian consensus glutamic acid (D53E) (swine
pH1N1 in Table 1 and Figure 4), a mutation that confers loss of
resistance to human MxA (Figure 5A), but not to porcine Mx1
(Figure 5B). This might suggest that MxA resistance-enhancing
mutations are not necessarily favorable for NP function and might
therefore cause impaired viral fitness.
To compare the replication fitness of viruses containing MxA-
sensitive or MxA-resistant NPs, we infected MDCKII cells (which
do not express antivirally active Mx proteins [36]) with pH1N1 or
mutant viruses with enhanced MxA sensitivity. A recombinant
pH1N1 virus with the single D53E reversion (pH1N1-NP-D53E)
grew equally well as the parental pH1N1 virus (Figure 5D). In
contrast, the pH1N1 precursor virus lacking three MxA resistance-
enhancing mutations (pH1N1-NP-D53E,V313F,M316I) grew to
approximately one log10 higher infectious titers throughout the
course of infection (Figure 5D). These results demonstrate that
reversions to the original amino acids of the putative swine
precursor virus (Figure 4) provided a strong growth advantage in
the absence of an antivirally active Mx. Thus, the acquisition of
MxA resistance appears to cause some growth disadvantage.
To confirm this hypothesis, we tested the human H5N1 strain
KAN-1 containing MxA resistance-enhancing mutations in
MDCKII cells. Consistent with previous observations [36], the
polymerase activity of H5N1 was not affected in the presence of
canine Mx1 or Mx2 (Figure S7B). The triple mutant H5N1-NP-
R100V,L283P,F313Y achieved reduced viral titers in the order of
1–2 log10 (Figure 5E). The recombinant H5N1 virus with the
single MxA resistance mutation L283P (H5N1-NP-L283P) grew
slightly less well than the parental H5N1 strain, while the double
mutant virus H5N1-NP-R100I,F313Y showed comparable growth
(Figure 5E). Intriguingly, the latter virus showed severely impaired
replication efficiency in avian LMH cells which lack antiviral Mx
proteins [37–39] (Figure S8). We conclude that MxA resistance is
linked to impaired viral growth and may be easily lost in the
absence of selective pressure.
Mx resistance-enhancing mutations in NP increase the
virulence of the H5N1 strain KAN-1 in Mx1-positive mice
We argued that the acquisition of Mx resistance should also
increase the pathogenicity of H5N1 in Mx1-positive mice. To test
Table 1. Conservation of amino acid positions in NP that are responsible for MxA resistance.
Host Subtypes 16D 53D 100I/V 283P 313V 313Y n=
Avian All 0.1 0.0 0.4 0.1 0.0 0.0 5350
Avian H5N1 0.0 0.0 0.0 0.1 0.0 0.0 1130
Human H5N1 0.0 0.0 0.5 0.5 0.0 0.0 187
Human H1N1 seasonal 98.2 0.1 99.7 98.2 0.0 98.4 1383
Human H1N2/H2N2/H3N2 99.5 0.0 99.8 99.5 0.0 99.4 3586
Swine Classical H1N1 0.0 0.0 99.5 0.0 0.0 0.0 393
Human pH1N1 0.3 100.0 99.9 0.0 99.8 0.0 4104
Swine pH1N1 0.0 83.2 97.5 0.0 98.3 0.0 119
Full-length NP protein sequences of the indicated subtype and host were downloaded at 19th of October 2012 from [24]. Sequences depicted as H1N1 seasonal exclude
H1N1 viruses of the pH1N1 lineage. Human pH1N1 refer to sequences of isolates found in humans. In avian sequences all available subtypes (H1-16, N1-9) were
included. Sequences depicted as swine classical comprise sequences of the North American classical swine influenza viruses and exclude viruses of the pH1N1 lineage.
The frequency of conserved residues is indicated in %. n = number of strains analyzed.
doi:10.1371/journal.ppat.1003279.t001
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this hypothesis we selected the double mutant virus H5N1-NP-
R100I,F313Y which had almost wild-type growth characteristics
in tissue culture (Figure 5E) and exhibited comparable polymerase
activity (Figure S8A), in spite of its Mx resistance-enhancing
mutations (Figure 1E). We could not include the triple mutant
virus H5N1-NP-R100V,L283P,F313Y in our studies due to the
emergence of escape mutants (data not shown) and its strong
attenuation. First, we compared the growth of wild-type and
mutant H5N1 viruses in Mx1-negative BALB/c mice. Infection
with 10 PFU of wild-type H5N1 virus lead to pronounced weight
loss and death of all animals, as expected [40]. In contrast,
infection with the same challenge dose (10 PFU) of mutant H5N1-
NP-R100I,F313Y virus resulted in survival of all BALB/c mice
without significant weight loss (Figure 6A and B), indicating that
the two amino acid substitutions associated with Mx resistance
caused impaired viral growth. Indeed, challenge of BALB/c mice
with 1000 PFU of the mutant virus resulted in viral lung titers that
were 15-fold reduced as compared to wild-type virus at 48 h after
infection (Figure 6C). Next, the growth properties of the two
viruses were studied in congenic Mx1-positive mice. In these
animals, infection with wild-type H5N1 virus produced no
pronounced pathological effects, even at high doses of 106 PFU
(Figure 6D and E). In contrast, Mx1-positive mice showed
significant weight loss and mortality when challenged with
106 PFU of mutant H5N1-NP-R100I,F313Y virus (Figure 6D
and E). To assess viral growth in Mx1-positive mice, viral lung
titers were determined at various time points after intranasal
infection with 104 PFU (Figure 6F). Two days after infection, the
titers in mice infected with the mutant virus were approximately
28-fold lower than those in mice infected with the wild-type virus,
demonstrating the attenuating effect of the Mx resistance-
enhancing mutations in NP. Four days after infection, a 5-fold
difference was observed, and 6 days after infection the mutant
virus was still present in 5 out of 9 Mx1-positive mice with titers up
to 26105 PFU. In contrast, only low titers of wild-type virus were
detected at the same time in 2 out of 9 animals. We conclude from
these experiments that H5N1 viruses harboring MxA resistance-
enhancing mutations partially overcome the antiviral effect
mediated by Mx1.
Discussion
Influenza A viruses sporadically transmit from the avian
reservoir into the human population. Here we describe specific
mutations found in the NP of the 1918 and 2009 pandemic viruses
that confer resistance to the IFN-induced human MxA GTPase, a
major restriction factor for influenza and other orthomyxoviruses.
As MxA strongly inhibits transcription and replication of the viral
genome early in infection, its antiviral activity can be readily
analyzed in polymerase reconstitution (minireplicon) assays
[20,21]. Using this assay, we identified a cluster of surface-exposed
amino acids in the body domain of NP crucial for Mx resistance.
Interestingly, different amino acid positions were identified in 1918
and pH1N1 NP, yet all were located in the same domain. All
resistance-associated amino acids are conserved in previous and
current human influenza A viruses (Table 1), and the continuing
acquisition of resistance-enhancing mutations (Figure 7) suggests
strong positive selection pressure by MxA. Of note, mutations
conferring MxA resistance are absent in avian influenza A viruses,
although we did observe the emergence of adaptive NP mutations
in avian-derived viruses circulating in swine (Figure 4 and
Figure 7). These substitutions in NP not only increased resistance
to swine Mx1 but also to human MxA, supporting the theory that
swine are an excellent intermediate host for the generation of
viruses with pandemic potential.
Influenza A viruses carrying a novel NP gene were introduced
into the human population in 1918 and 2009 [10,27], but the
distinct MxA resistance clusters in the NP genes of these pandemic
viruses suggest independent evolution (Figure 7). In case of the
2009 pH1N1 virus, the NP gene originated from the classical
swine lineage, which itself is of avian origin [41]. Our data suggest
that the swine precursor virus of pH1N1 acquired additional
amino acid changes, which together increased the ability to
counteract human MxA. The evolution of the 1918 NP is
comparatively less clear. Recent data suggest that both the 1918
and the classical swine virus lineage share a common avian
ancestor [9]. It is unresolved whether the avian precursor virus was
first transmitted to humans and then onto swine or vice versa [9].
In the latter case, the precursor virus may have first adapted to
swine Mx1 through the mutation R100I in NP which is found in
early swine isolates [24]. In the first case, mutations at position 283
and 313 might have been lost after transmission from humans to
swine, as observed with the pH1N1 virus. However, analyses of
host specificity markers which discriminate human from avian
influenza viruses indicate that four adaptive mutations in NP (16D,
283P, 313Y and 357K) were likely required for transmission of the
1918 precursor virus to humans [42]. Remarkably, all of these
mutations contribute to MxA resistance (Figure 3) and may have
evolved in a pre-pandemic phase in the human population. Since
circulating human influenza A virus strains maintain these
adaptive mutations (Table 1), it is conceivable that viruses are
under constant selection pressure mediated by MxA.
We observed that the acquisition of Mx resistance had a
negative effect on viral growth in the absence of MxA. When MxA
resistance-enhancing mutations were introduced into highly
pathogenic avian H5N1 viruses, the recombinant viruses grew
less well than the wild-type H5N1 virus in MxA-negative
MDCKII cells (Figure 5E), in BALB/c mice (Figure 6C) and
even in avian cells (Figure S8). These mutations have no major
effect in the viral polymerase reconstitution assay (Figure S1C and
S3), and it is unclear which step of the viral replication cycle is
attenuated in infected cells. If MxA resistance-associated amino
acids are also counter-selected in circulating avian influenza
strains, then the emergence of MxA resistance in the avian
reservoir is expected to be an extremely rare event (Table 1). Of
note, human H5N1 isolates have developed few if any of the
identified MxA resistance-enhancing mutations (Table 1), most
likely due to the associated strong attenuation [43] (Figure 5E, 6A–
C). Perhaps for this reason, the 1957 and 1968 pandemic viruses
retained the well-adapted 1918-origin NP, despite acquiring other
Figure 4. Phylogenetic analysis of representative NP sequences and the presence or loss of Mx-resistance enhancingmutations. The
maximum likelihood tree of 147 aligned representative NP sequences shows four genotypes, i.e., (i) the human seasonal H1N1, H2N2 and H3N2
viruses, (ii) the classical swine H1N1 viruses and pandemic (2009) H1N1 viruses, (iii) the European lineages of swine influenza viruses, and (iv) the
North American avian influenza viruses. Strain designations and GenBank acc. nos. are presented. Numbers at nodes indicate bootstrap values
obtained after 1,000 replications. Only bootstrap values greater 50% were presented. The bar indicates substitutions per site. Three branches (H2N2/
H3N2, recent human H1N1 strains, European lineages of swine influenza viruses) were condensed for clarity. The complete phylogenetic tree is
shown in Figure S5. No relevant amino acid substitutions were observed in the condensed branches. Alterations of amino acid positions shown to
influence Mx resistance (Figure 3, Figure S9) are highlighted in bold.
doi:10.1371/journal.ppat.1003279.g004
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Figure 5. Mx resistance is accompanied by impaired viral growth in cell culture. (A–B) H5N1 polymerase activity in HEK293T cells after co-
transfection of the indicated expression plasmids coding for NP (100 ng) and MxA (200 ng) (A) or porcine Mx1 (poMx1) (200 ng) (B). The activity in
the presence of human MxA or poMx1 was normalized to the activity observed with the inactive mutant MxA-T103A. The activity observed with
pH1N1 NP was set to 100%. Error bars indicate the standard error of the mean of three independent experiments. Student’s t-test was performed to
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avian genome segments by reassortment. Thus, more than 90
years passed before a new NP lineage was established 2009 in
humans, a process aided by gradual adaptation of the new NP in
swine.
Correspondingly, we observed an increase in viral growth of
pH1N1 lacking the MxA resistance-enhancing mutations D53,
V313 and M316 in MDCKII cells (Figure 5D) which do not
express antivirally active Mx proteins [36]. We therefore propose
that passage of viruses in hosts with weak or inactive Mx proteins
(such as swine or laboratory mouse strains, respectively) would
result in a loss of MxA resistance. In fact, experimental adaptation
of the pandemic 2009 virus to Mx1-negative mice led to the
acquisition of mutations in NP which strongly diminished Mx
resistance, such as D101G [44] (Figure S9). Similarly, mutations
conferring MxA resistance were lost (D53E, D101G, H289L)
following re-transmission of pH1N1 from human to swine
(Figure 4).
The mechanism by which MxA exerts its antiviral function
during infection or in the polymerase reconstitution assays is
presently not known. MxA may block the viral life cycle at
several early steps by interfering with the processes of vRNP
entry and intracellular transport [45], as well as primary [45]
and secondary transcription [46]. We proposed a model in which
MxA recognizes vRNPs and begins to self-assemble into rings,
thereby sterically inhibiting vRNP function [15,18,19]. This
model has recently been suggested also for mouse Mx1, but in a
modified version involving in addition also the polymerase
subunit PB2 [28], in agreement with previous functional work
implicating PB2 as putative target of mouse Mx1 [47,48].
Modeling the present MxA resistance clusters into the available
vRNP structure [49] revealed that the sites on NP are most likely
solvent-exposed, and thus accessible to cellular factors. Initial
contact of MxA to single binding sites on NP might be weak but
reinforced by oligomerization, involving multiple repetitive
contacts exposed on the many NP molecules that form the
vRNP. Weak but extensive contacts to repetitive viral target
motifs have been demonstrated for other intracellular restriction
factors. For example, TRIM5a specifically binds to several
surface-exposed amino acids of the capsid protein of HIV-1,
thereby forming an array or lattice on top of the viral capsid
[50,51]. To date, physical interaction between influenza A virus
NP and MxA could be demonstrated after covalent protein
crosslinking [52] and thus MxA might also bind to free NP in the
cytoplasm thereby blocking polymerase activity indirectly.
However, it is also likely that further cellular proteins modulate
MxA activity and its interaction with viral proteins. Previous
work identified a number of potential MxA co-factors, but their
contribution is still unclear [53–56]. One promising candidate is
the helicase UAP56, a DEAD box RNA helicase which was
shown to prevent double-strand RNA formation and subsequent
innate immune activation in influenza virus-infected cells.
UAP56 binds both MxA and NP [29,57], in the latter case via
the N-terminal domain of NP which contains the MxA
resistance-enhancing mutation G16D [58]. Nonetheless, the
significance of this observation and the role of UAP56 for
antiviral activity remain to be demonstrated.
In summary, we have found functional and evolutionary
evidence that the human MxA GTPase provides an efficient
barrier against zoonotic introduction of influenza A viruses into
the human population. Thus, the human MxA is a significant
driving force in influenza A virus nucleoprotein evolution. We
therefore propose that amino acids known to contribute to MxA
resistance should be monitored as a strong indicator for the
pandemic potential of newly emerging influenza A viruses.
Materials and Methods
Ethics statement
All animal experiments were performed in compliance with the
German animal protection law (TierSchG). The mice were housed
and handled in accordance with good animal practice as defined
by FELASA (www.felasa.eu/guidelines.php) and the national
animal welfare body GV-SOLAS (www.gv-solas.de/index.html).
The animal welfare committees of the university of Freiburg, as
well as the local authorities (Regierungspra¨sidium Freiburg)
approved all animal experiments.
Cells
Canine MDCKII, porcine NSK and NPTr cells [34], and
human HEK 293T cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10%
fetal calf serum, 2 mM L-glutamine and 1% penicillin-strepto-
mycin. Chicken hepatocellular epithelial cell line (LMH) [59]
was grown in DMEM supplemented with 8% fetal calf serum
2% chicken serum, 2 mM L-glutamine and 1% penicillin/
streptomycin.
Plasmid constructions
The pHW2000 rescue plasmids [60] and pCAGGS expression
plasmids [61] coding for NP were used for site directed
mutagenesis. The coding region of MxA was cloned into
pCAGGS, whereas murine Mx1 was expressed using pcDNA
3.1 [21]. The cDNA of porcine Mx1 (poMx1) corresponding to
the full length 1992 nt long open reading frame as described in
[62], encoding a Flag tag at its 59-end was cloned into pCAGGS
using KpnI and XhoI. poMx1 cDNA was generated from mRNA
isolated from IFNa-2a-treated cell cultures from domestic pig (Sus
scrofa domestica).
Generation of recombinant influenza A viruses
The recombinant viruses A/Hamburg/4/09 (pH1N1) and A/
Thailand/1(KAN-1)/04 (H5N1), and the NP-mutant viruses
were generated by the eight-plasmid reverse-genetics system as
described previously [21]. All recombinant viruses were plaque
purified on MDCKII cells. Virus stocks were prepared on
MDCKII cells and titers were determined by plaque assay.
Reconstitution of the influenza virus polymerase
(minireplicon)
HEK 293T cells seeded in 12-well plates were transfected using
the Nanofectin transfection reagent (PAA Laboratories) according
to the manufacturer’s protocol. 10 ng of pCAGGS plasmids
encoding PB2, PB1, and PA and 100 ng of NP-encoding plasmid
were cotransfected with 100 ng of the firefly luciferase- encoding
viral minigenome construct pPolI-FFLuc-RT, which is flanked by
the noncoding regions of segment 8 of influenza A virus. The
determine the P value. **P,0.01, ***P,0.001; NS, not significant. (C) Expression levels of human MxA and poMx1 in HEK293T cells after reconstitution
of the H5N1 polymerase complex using an Mx-specific antibody. (D–E) MDCKII cells were infected with an MOI of 0.001 of wild-type or the indicated
pH1N1 (D) or H5N1 mutant viruses (E) and incubated at 37uC. At the indicated time points post infection (p.i.), virus titers were determined by plaque
assay. Error bars indicate the standard error of the mean of three independent experiments.
doi:10.1371/journal.ppat.1003279.g005
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Figure 6. Mx resistance-enhancing mutations in NP increase the virulence of the H5N1 isolate KAN-1 in Mx1-positive mice. (A–C)
BALB/c mice were inoculated intranasally with the indicated amount of viruses. Changes in body weight (A) or survival (B) (n=6/group) were
monitored daily for 14 days. Lungs from infected mice were collected 2 days p.i., homogenized and virus titers were determined by plaque assay (C).
Molecular Determinants of MxA Resistance
PLOS Pathogens | www.plospathogens.org 12 March 2013 | Volume 9 | Issue 3 | e1003279
transfection mixture also contained 30 ng of pRL-SV40, a plasmid
constitutively expressing Renilla luciferase under the control of the
simian virus 40 promoter to normalize variations in transfection
efficiency. To evaluate the antiviral potential of Mx1 and MxA, we
cotransfected Mx1- or MxA- encoding plasmid. A simultaneous
experiment with cotransfection of the antivirally inactive mutants
Mx1-K49A or MxA-T103A, respectively, was used as a control.
To achieve equal amounts of transfected DNA, an empty vector
plasmid was added. Twenty-four hours post transfection, cells
were lysed and firefly and Renilla luciferase activities were
measured using the dual luciferase reporter assay (Promega)
according to the manufacturer’s protocol. Reconstitution of the
viral polymerase complex in avian and porcine cells was
performed as above with the exception that the minigenome
RNA was expressed under the control of a chicken [63] or porcine
Pol I promoter (pSPOM2) [34].
Virus growth curves
MDCKII cells seeded in 6-well plates were incubated with virus
at a multiplicity of infection (MOI) of 0.001 in PBS+/+ containing
0.2% BSA for 1 h at 37uC. The inoculum was removed and 3 ml
infection medium (DMEM supplemented with 0.2% BSA),
additionally containing 1 mg/ml TPCK-treated trypsin for
pH1N1 viruses, was added. Virus titers in cell culture supernatants
were determined at the indicated time points by plaque assay and
are expressed as PFU per ml.
Primer extension analysis
For determination of viral transcript levels in virus-infected
MDCKII cells, cells were seeded in 6-well plates and infection was
carried out with infection media. After the indicated time point
post infection, cells were harvested in TrizolTM and RNA was
purified according to the manufacturer’s protocol (Invitrogen).
(D–F) Mx1-positive BALB/c mice were inoculated intranasally with the indicated amount of viruses. Changes in body weight (D) or survival (E) (n= 6/
group) were monitored daily for 14 days. Lungs from infected mice were collected 2, 4, and 6 days p.i., homogenized and virus titers were determined
by plaque assay (F). Student’s t-test was performed to determine the P value. *P,0.05, **P,0.01, ***P,0.001; NS, not significant.
doi:10.1371/journal.ppat.1003279.g006
Figure 7. Temporal appearance of MxA resistance enhancing amino acids in NP of human and swine influenza A viruses. Bold letters
indicate amino acids in NP shown to increase significantly MxA resistance, whereas amino acids highlighted in grey are minor contributors. Adaptive
mutations that newly emerged with the appearance of the 2009 pandemic pH1N1 strain are depicted in red. 53D got partially lost after re-
introduction of pH1N1 into the swine host.
doi:10.1371/journal.ppat.1003279.g007
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Primer extension analysis was performed as described [63] using
specific primers for the NA segment (mRNA, cRNA and vRNA)
and cellular 5sRNA.
Animal experiments
BALB/c mice were obtained from Janvier (Straßburg) and
congenic BALB.A2G-Mx1 mice (designated BALB-Mx1) carrying
the functional Mx1 allele [64] were bred locally. Six- to eight-
week-old mice were anesthetized with a mixture of ketamine
(100 mg per gram body weight) and xylazine (5 mg per gram)
administered intraperitoneally (i.p.) and inoculated intranasally
(i.n.) with the indicated doses of viruses in 50 ml phosphate-
buffered saline (PBS) containing 0.2% bovine serum albumin
(BSA). Mice were monitored daily for weight loss until 14 days
postinfection (p.i.). Animals with severe symptoms or more than
25% weight loss were euthanized. Lung homogenates were
prepared using the FastPrep24 system (MP Biomedicals). Briefly,
after addition of 800 ml of PBS containing 0.2% BSA, lungs were
subjected to two rounds of mechanical treatment for 10 s each at
6.5 m/s. Tissue debris was removed by low-speed centrifugation.
The LD50 values were calculated based on the infectious dose
(PFU). All animal work was conducted under BSL 3 conditions in
accordance with the guidelines of the local animal care committee.
Molecular modeling
The program PyMOL (www.pymol.org) was used to assign the
indicated positions in the structural model of the NP of A/HK/
483/97(H5N1) (PDB code:2Q06). The program I-TASSER
(zhanglab.ccmb.med.umich.edu/I-TASSER) was used to generate
a full length NP model of A/Thailand/1(KAN-1)/04 (H5N1),
including amino acids 1–20.
Alignments and phylogenetic analyses
Alignments and phylogenetic analyses were conducted with
MEGA5 [65]. For maximum likelihood (ML) tree inference, the
GTR substitution model assuming gamma distribution (four
gamma categories) and invariant sites was selected, and the initial
tree was made automatically. Bootstrap analysis was performed
with 1,000 replications. The optimal substitution model was
selected on the basis of the Bayesian information criterion (BIC)
and the corrected Akaike information criterion (AICc) using a
model test implemented in MEGA5.
Supporting Information
Figure S1 Polymerase activities in the presence of Mx1
or the antivirally inactive mutant Mx1-K49A. (A) Reporter
activity of 1918 polymerase. HEK293T cells were transfected with
expression plasmids coding for PB2, PB1 and PA of the pandemic
1918 strain, the indicated NP proteins, the firefly luciferase
encoding minigenome, 200 ng Mx1-encoding plasmid and a
Renilla-expressing plasmid to normalize variation in transfection
efficiency. Polymerase activity in the presence of antivirally
inactive Mx1-K49A was used to normalize the data obtained
with Mx1. Activity in the presence of the 1918*-NP was set to
100%. Error bars indicate the standard error of the mean of three
independent experiments. Student’s t-test was performed to
determine the P value. **P,0.01. (B) 1918 polymerase activity
in the presence of the antivirally inactive mutant Mx1-K49A.
HEK293T cells were transiently transfected with expression
plasmids coding for the vRNP components as described in (A)
including 200 ng of Mx1-K49A-encoding plasmid. Renilla activity
was used to normalize variation in transfection efficiency. The
polymerase activity in the presence of the 1918*-NP was set to
100%. Error bars indicate the standard error of the mean of three
independent experiments. Student’s t-test was performed to
determine the P value. NS, not significant. (C) H5N1 polymerase
activity in the presence of either Mx1, the antivirally inactive
mutant Mx1-K49A or empty vector. HEK293T cells were
transiently transfected with expression plasmids coding for the
vRNP components of H5N1 including 200 ng of Mx1, Mx1-
K49A-encoding plasmid or empty vector and the indicated NP
mutants. Renilla activity was used to normalize variation in
transfection efficiency. The polymerase activity in the presence of
the 1918-NP was set to 100%. Error bars indicate the standard
error of the mean of three independent experiments. Student’s t-
test was performed to determine the P value. *P,0.05, **P,0.01,
***P,0.001; NS, not significant.
(PDF)
Figure S2 Identification of amino acids in 1918 NP
responsible for MxA resistance. Reporter activity of the
H5N1 polymerase in HEK293T cells after co-transfection of the
expression plasmids coding for MxA (200 ng) and the indicated
NP proteins (100 ng). The activity in the presence of MxA was
normalized to the activity observed with the antivirally inactive
mutant MxA-T103A. The activity observed with the 1918*-NP
was set to 100%.
(PDF)
Figure S3 Polymerase activities in the presence of the
antivirally inactive mutant MxA-T103A. H5N1 polymerase
reporter activity was determined after co-transfection of expression
plasmids coding for the indicated NP mutants (100 ng) and the
antivirally inactive mutant MxA-T103A (200 ng). The reporter
activity observed with the 1918-NP was set to 100%. Error bars
indicate the standard error of the mean of three independent
experiments. Student’s t-test was performed to determine the P
value. *P,0.05, **P,0.01; NS, not significant.
(PDF)
Figure S4 Localization of the adaptive mutation 16D in
NP. The model for the full-length structure of H5N1 NP (A/
Thailand/1(KAN-1)/04) harboring the mutations G16D, R100I,
L283P and F313Y was generated utilizing I-TASSER. The N-
terminus that was not resolved in the crystal structure (aa 1–20) is
highlighted in light orange, whereas 1918-specific amino acids that
confer Mx resistance are shown in blue (16D, 100I/V, 283P and
313Y).
(PDF)
Figure S5 Phylogenetic analysis of representative NP
sequences and the presence or loss of Mx-resistance
enhancing mutations. The maximum likelihood tree of 147
aligned sequences shows four genotypes, i.e., (i) the human H1N1,
H2N2 and H3N2 viruses, (ii) the classical swine H1N1 viruses and
pandemic (2009) H1N1 viruses, (iii) the European lineages of swine
influenza viruses, and (iv) the North American avian influenza
viruses. Strain designations and GenBank acc. nos. are presented.
Numbers at nodes indicate bootstrap values obtained after 1,000
replications. Only bootstrap values greater than 50% are
presented. The bar indicates substitutions per site. Alterations of
amino acid positions shown to influence Mx resistance (Figure 3,
Figure S9) are highlighted in bold.
(PDF)
Figure S6 Mx resistance of NP variants of swine origin.
(A–B) H5N1 or (C) pH1N1 polymerase activity in the presence of
human MxA (A and C) or porcine Mx1 (poMx1) (B). The activity
in the presence of human MxA or poMx1 was normalized to the
activity observed after co-expression of the antivirally inactive
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MxA mutant MxA-T103A. The activity observed with the
pH1N1-NP was set to 100%, respectively. Error bars indicate
the standard error of the mean of three independent experiments.
Student’s t-test was performed to determine the P value.
**P,0.01, ***P,0.001; NS, not significant.
(PDF)
Figure S7 Inhibition of polymerase activities by porcine
and canine Mx proteins. (A) Swine NPTr or NSK cells were
transfected with expression plasmids coding for NP, PB2, PB1 and
PA of H5N1, the porcine Pol1-driven firefly luciferase encoding
minigenome, 200 ng of either porcine Mx1 (poMx1), MxA, or the
GTPase-inactive MxA mutant MxA-T103A and a Renilla-
expressing plasmid to normalize variation in transfection efficien-
cy. The activity in the presence of MxA-T103A was set to 100%.
Error bars indicate the standard error of the mean of three
independent experiments. Student’s t-test was performed to
determine the P value. **P,0.01; ***P,0.001. (B) HEK293T
cells were transfected with expression plasmids coding for NP,
PB2, PB1 and PA of H5N1, the firefly luciferase encoding
minigenome, 200 ng of either canine Mx1 (cMx1), canine Mx2
(cMx2), MxA or the GTPase-inactive MxA mutant MxA-T103A
and a Renilla-expressing plasmid to normalize variation in
transfection efficiency. The activity in the presence of MxA-
T103A was set to 100%. Error bars indicate the standard error of
the mean of three independent experiments. Student’s t-test was
performed to determine the P value. ***P,0.001; NS, not
significant.
(PDF)
Figure S8 Mx resistance-enhancing mutations influence
transcription and viral growth in avian cells. (A)
Comparison of viral transcription in MDCKII or avian LMH
cells infected with an MOI of 5 of either H5N1 (KAN-1) or H5N1-
NP-R100I,F313Y after the indicated hours post infection (h.p.i.).
mRNA, cRNA, and vRNA levels were determined using primer
extension analysis with primers specific for segment 6. Levels of
cellular 5sRNA served as internal control. (B) Avian LMH cells
were infected with an MOI of 0.001 of either H5N1 or H5N1-NP-
R100I,F313Y and incubated at 37uC. At the indicated time points
post infection (p.i.), virus titers were determined by plaque assay.
Error bars indicate the standard error of the mean of three
independent experiments.
(PDF)
Figure S9 Mutation D101G in NP of pH1N1 strongly
reduces resistance to MxA. H5N1 polymerase activity after
co-transfection of MxA (200 ng) and the indicated NP (100 ng)
expression plasmids. The activity in the presence of MxA was
normalized to the activity observed with the antivirally inactive
mutant MxA-T103A. The reporter activity observed with the
pH1N1-NP in the presence of MxA was set to 100%. Error bars
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